There are implications for two of the core aims of Australia's well respected national medicines policy flowing from the preceding sketch of developments in international markets. First, 'access to medicines', that is, the future of the PBS and, second, a 'responsible and viable industry in Australia', that is, the promotion of business activity in the biopharma sector. Plainly, the expiry of many drug patents, and the strengthening of the global generics sector, opens up opportunities for PBS measures to extend the use of cheaper generics. This is a recognition which underpins ...